Skyepharma PLC Says Abbott Laboratories Quits Flutiform Partnership

LONDON, Aug 19 (Reuters) - Britain's SkyePharma (SKP.L) said Abbott Laboratories (ABT.N) has ended its deal to market SkyePharma's asthma drug Flutiform in the United States, after regulators imposed what could be insurmountable hurdles to approval.